Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners
November 1, 2024 7:19 AM EDTLeerink Partners analyst Andrew Berens lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $880.00 (from $1,077.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are reducing our REGN PT from $1,077 (22x old 2025E EPS of $48.96) to $880 (20x new 2025E EPS of $44.01). We... More
CFRA Downgrades Regeneron Pharma (REGN) to Hold
October 31, 2024 4:11 PM EDTCFRA downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold with a price target of $950.00.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $922.79 yesterday.
... MoreRegeneron (REGN) Tops Q3 EPS by 74c
October 31, 2024 6:42 AM EDTRegeneron (NASDAQ: REGN) reported Q3 EPS of $12.46, $0.74 better than the analyst estimate of $11.72. Revenue for the quarter came in at $3.72 billion versus the consensus estimate of $3.66 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... MorePiper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
October 29, 2024 4:03 PM EDTPiper Sandler analyst Christopher Raymond reiterated an Overweight rating and $1,242.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "Remain OW rated on REGN shares, and highlight herein what we see as meaningful short- and longer-term crosswinds for the Eylea... More
